Brief: Gracell Biotechnologies Announces FDA Clearance Of Ind Application For Phase 1B/2 Clinical Trial Of Fastcar-T Gc012f
03/02/2023 12:51
Feb 3 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES ANNOUNCES FDA CLEARANCE OF THE IND
APPLICATION FOR PHASE 1B/2 CLINICAL TRIAL OF FASTCAR-T GC012F
FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
* GRACELL BIOTECHNOLOGIES INC - COMPANY PLANS TO INITIATE
PHASE
1B/2 CLINICAL TRIAL IN U.S. IN Q2 OF 2023
* GRACELL BIOTECHNOLOGIES INC - PLANS TO INITIATE PHASE 1B/2
CLINICAL TRIAL IN U.S. IN Q2 OF 2023
* GRACELL BIOTECHNOLOGIES-BCMA/CD19 DUAL-TARGETING FASTCAR-T
GC012F SHOWED DEEP RESPONSES, FAVORABLE SAFETY PROFILE IN PROOF
OF CONCEPT CLINICAL STUDIES
Source text for Eikon: ID:nPn4Sz3rWa
Further company coverage: GRCL.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27